Bioenvision is currently developing products for a wide range of solid tumors (including breast, prostate, colorectal, pancreatic and bladder) and hematologic malignancies (including acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia and lymphoma). Bioenvision is planning to develop products for other therapeutic areas as well. In addition, the Company has in-licensed technologies to reduce the impact of blood-borne and hospital-acquired infections.